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Abstract
Background: Promising clinical data and significant antigen-sparing have been demonstrated for a pandemic
H5N1 influenza split-virion vaccine adjuvanted with AS03A,a na-tocopherol-containing oil-in-water emulsion-based
Adjuvant System. Although studies using this formulation have been reported, there have been no data for
Japanese populations. This study therefore aimed to assess the immunogenicity and tolerability of a prepandemic
(H5N1) influenza vaccine adjuvanted with AS03A in Japanese adults.
Methods: This open-label, single-group study was conducted at two centres in Japan in healthy Japanese males
and females aged 20-64 years (n = 100). Subjects received two doses of vaccine, containing 3.75 μg
haemagglutinin of the A/Indonesia/5/2005-like IBCDC-RG2 Clade 2.1 (H5N1) strain adjuvanted with AS03A, 21 days
apart. The primary endpoint evaluated the humoral immune response in terms of H5N1 haemagglutination
inhibition (HI) antibody titres against the vaccine strain (Clade 2.1) 21 days after the second dose. Ninety five
percent confidence intervals for geometric mean titres, seroprotection, seroconversion and seropositivity rates were
calculated. Secondary and exploratory endpoints included the assessment of the humoral response in terms of
neutralising antibody titres, the response against additional H5N1 strains (Clade 1 and Clade 2.2), as well as the
evaluation of safety and reactogenicity.
Results: Robust immune responses were elicited after two doses of the prepandemic influenza vaccine adjuvanted
with AS03A. Overall, vaccine HI seroconversion rates and seroprotection rates were 91% 21 days after the second
vaccination. This fulfilled all regulatory acceptance criteria for the vaccine-homologous HI antibody level. A
substantial cross-reactive humoral immune response was also observed against the virus strains A/turkey/Turkey/1/
2005 (Clade 2.2) and A/Vietnam/1194/2004 (Clade 1) after the second vaccine administration. A marked post-
vaccination response in terms of neutralising antibody titres was demonstrated and persistence of the immune
response was observed 6 months after the first dose. The vaccine was generally well tolerated and there were no
serious adverse events reported.
Conclusions: The H5N1 candidate vaccine adjuvanted with AS03A elicited a strong and persistent immune
response against the vaccine strain A/Indonesia/5/2005 in Japanese adults. Vaccination with this formulation
demonstrated a clinically acceptable reactogenicity profile and did not raise any safety concerns in this population.
Trial registration: Clinicaltrials.gov NCT00742885
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The highly pathogenic influenza A H5N1 virus first
emerged as a cause of death in poultry in 1996 and was
identified in humans in 1997; 18 individuals in Hong
Kong became severely ill, with six deaths reported, fol-
lowing contact with infected birds [1]. The H5N1 virus
reappeared in 2003 and has since caused 295 deaths
from 499 confirmed cases worldwide (World Health
Organization [WHO] as of 08 June 2010) [2].
The WHO declared a pandemic alert stage 6 due to
an outbreak of an influenza A virus (A/H1N1) on 11
June 2009. As of 13 June 2010, more than 214 countries
have reported a total of at least 18,172 deaths [3]. How-
ever, the highly pathogenic H5N1 strain is also a poten-
tial pandemic virus and, therefore, it remains of great
concern. The H5N1 virus currently meets two of the
t h r e ec r i t e r i af o rag l o b a lp a n d e m i cs t r a i n :H 5i sah a e -
magglutinin (HA) subtype against which most of the
human population is virtually naïve, and the virus is
able to replicate in humans causing severe disease and
death [4]. To date, the virus has not acquired the ability
for large-scale human-to-human transmission - although
isolated cases have occurred [5,6].
Vaccination is a vital part of the strategy to mitigate
morbidity and mortality caused by influenza pandemics
[7] and is integral to the WHO global influenza prepared-
ness plan [8]. Pandemic vaccines are produced as soon as
a pandemic is declared using the specific pandemic viral
strain. However, these vaccines will only be available sev-
eral months after the onset of the pandemic due to the
length of time required for their manufacture [8].
The efficacy of prepandemic vaccines, which are pro-
duced in advance of a pandemic, relies on the vaccine’s
ability to provide a breadth of protection against differ-
ent, related strains, as it is not possible to predict exactly
the strain that will cause such an outbreak in advance
due to the progressive accumulation of antigenic
changes.
Promising clinical data have been generated for a pre-
pandemic split-virion influenza vaccine formulated with
an a-tocopherol containing, oil-in-water (O/W) emul-
sion-based Adjuvant System, AS03. This vaccine has
demonstrated a good safety profile in randomised clini-
cal trials in a range of human populations [9-11]. AS03
adjuvantation of the H5N1 vaccine allows for a reduc-
tion in the amount of antigen required per dose in
order to induce potentially protective immune responses
in humans, and it can also induce strong cross-strain
and cross-clade immunity as is required for an effective
prepandemic vaccine [9,10,12,13]. The A/Vietnam/1194/
2004 H5N1 strain was identified as having the potential
to cause a human pandemic and was thus used in sev-
eral AS03 candidate vaccine studies, leading to the
initial approval of a prepandemic H5N1 vaccine (Pre-
pandrix™ GSK Biologicals, Rixensart, Belgium)
[9,10,12-14]. This vaccine has also been shown to pro-
tect against lethal heterologous challenge in an animal
model [15]. A new emerging H5N1 strain was identified
by the WHO sentinel laboratory (A/Indonesia/5/2005)
in 2005 [16], which was subsequently recommended by
the WHO for use in vaccines, and has also been
employed as part of a potential prepandemic vaccine.
In January 2004, there were confirmed outbreaks of
H5N1 infection in Japanese poultry, which led to
increasing concern regarding the ability of the virus to
infect humans. Following the development of a whole-
virus, aluminium-adjuvanted H5N1 vaccine in 2007, the
Japanese Ministry of Health, Labour and Welfare began
domestic manufacture of this vaccine for stockpiling
[17]. However, the immune response elicited by an alu-
minium-adjuvanted H5N1 vaccine indicated insufficient
immunogenicity [18]. Clinical data on the use of alterna-
tive vaccines, such as the AS03-adjuvanted prepandemic
H5N1 vaccine, in the Japanese population would there-
fore be of interest.
This open-label, single-arm study set out to evaluate
the humoral immune response and safety of two doses
of AS03A-adjuvanted A/Indonesia/5/2005 H5N1 vaccine
and determine its putative clinical value as a prepan-
demic vaccine in healthy Japanese adults.
Methods
Vaccine
The A/H5N1 monovalent split-virion recombinant influ-
enza prepandemic candidate vaccine was manufactured
by GlaxoSmithKline (GSK) Biologicals in Quebec,
Canada. The vaccine contained 3.75 μgH Ao ft h eA /
Indonesia/5/2005-like IBCDC-RG2; Clade 2.1 (H5N1)
strain (Centers for Disease Control and Prevention
[CDC], Atlanta, USA) adjuvanted with AS03A (an O/W
emulsion-based Adjuvant System containing 11.86 mg
of a-tocopherol).
Study design
This open-label, single-group study (NCT00742885) was
conducted at two centres in Japan. The study set out to
evaluate the humoral immune response generated by
two doses of the adjuvanted prepandemic A/Indonesia/
5/2005 H5N1 vaccine in terms of H5N1 haemagglutina-
tion inhibition (HI) antibody titres against the vaccine
strain (Clade 2.1) 21 days after the second dose. Second-
ary and exploratory endpoints included the assessment
of the humoral response in terms of neutralising anti-
body titres, the response against additional H5N1 strains
(Clade 1 and Clade 2.2), as well as the evaluation of
safety and reactogenicity. The latter were assessed in
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adverse events (AEs), unsolicited AEs, serious AEs
(SAEs) and by the evaluation of medically attended visits
and selected laboratory parameters.
Healthy Japanese men and women aged between 20
and 64 years at the time of first vaccination were eligible
for inclusion if they were in good general health and
provided written informed consent before enrolment.
Subjects were stratified by age (20-40 years and 41-64
years) in a 1:1 ratio. Subjects were excluded from the
study if they had an axillary temperature ≥37.5°C, or
a c u t es y m p t o m so fm o r et h a nm i l ds e v e r i t yo nt h e
scheduled date of first vaccination; any confirmed or
suspected immunosuppressive or immunodeficient con-
dition including history of human immunodeficiency
virus (HIV) infection; administration of any registered
vaccine within 30 days before study vaccination or
planned administration within the first vaccination per-
iod up to blood sampling at Day 42; use of any investi-
gational or non-registered product (drug or vaccine)
within 30 days prior to study enrolment or planned use
during the study period, and history of previous H5N1
vaccination; or history of H5N1 influenza infection.
Subjects received two doses of the prepandemic
(H5N1) influenza candidate vaccine. The vaccine was
administered intramuscularly in the deltoid region of
the non-dominant arm on Day 0 and the second dose
was given 21 days later in the non-dominant arm. Blood
samples were collected for serological testing on Day 0,
7, 21, 42 and 182, and telephone contact was made on
Day 84 to record any unsolicited AEs (Figure 1). Soli-
cited AEs were assessed up to 7 days after each vaccina-
tion and, additionally, unsolicited AEs, including SAEs,
were recorded throughout the duration of the study.
The protocol and study documents were approved by
the Institutional Review Boards of the respective study
centres - National Hospital Organization Tokyo
National Hospital and Haradoi Hospital. The study was
conducted in accordance with Good Clinical Practice
(GCP) and the Declaration of Helsinki. GSK Biologicals
(Wavre, Belgium) sponsored the study and was involved
in all stages of the study conduct, including analysis of
data. All authors had full access to the data and were
involved in the analysis of data and preparation of the
manuscript.
Assessment of immunogenicity
The humoral immune response against the vaccine strain
(A/Indonesia/5/2005; Clade 2.1), as well as against the het-
erologous strains (A/turkey/Turkey/1/2005; Clade 2.2 and
A/Vietnam/1194/2004; Clade 1) was measured in terms of
the standard HI antibody response according to the guide-
lines of the Committee for Medicinal Products for Human
Use (CHMP) [19]. In addition, neutralising antibodies
against the vaccine (A/Indonesia/5/2005) and one hetero-
logous strain (A/Vietnam/1194/2004) were measured by
the microneutralisation (MN) assay and are further
referred to as H5N1 neutralising antibodies. Studies have
s h o w nt h a tn e u t r a l i s a t i o na s s a y sm a yb em o r es e n s i t i v e
than the HI test in detecting both greater increases in anti-
body levels and in detecting infected individuals who are
seronegative according to the HI assay [20].
Specific HI antibody titres were determined at GSK
Biologicals’ laboratories using methods described else-
where [21]. Antibody titre measurements were con-
ducted on thawed frozen serum samples with a
standardised and validated micromethod using four hae-
magglutination-inhibiting units (HIU) of the appropriate
antigens and a 0.5% horse erythrocyte suspension. Non-
specific serum inhibitors were removed by subjecting
the sera to heat treatment (56°C) and receptor-destroy-
ing enzyme. The sera obtained were evaluated for HI
antibody levels. Starting with an initial dilution of 1:10,
a dilution series (by a factor of 2) was prepared up to an
end dilution of 1:20,480. The titration endpoint was
taken as the highest dilution step that showed complete
inhibition (100%) of haemagglutination. All assays were
performed in duplicate.
The titre of H5N1 virus neutralising antibody contained
in the serum was determined by an MN assay on thawed
frozen serum samples. Each sample was tested in tripli-
cate. Non-specific serum inhibitors were removed by sub-
jecting the sera to heat treatment (56°C). A standardised
amount of virus (100 infectious Unit [TCID50] in 0.05
mL) was mixed with serial dilutions of sera and incubated
to allow binding of the antibodies to the virus. A cell sus-
pension, containing a defined number of Madin-Darby
canine kidney (MDCK) cells was then added to the mix-
ture of virus and antiserum and incubated at 33°C for 7
days. After the incubation period, virus replication was
visualised by haemagglutination of chicken red blood cells.
The 50% neutralisation titre of a serum was calculated by
the method of Reed and Muench [22].
Assessment of safety
Adverse events were classified according to the Medical
Dictionary for Regulatory Activities (MedDRA). The
Figure 1 Trial profile.
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selves using diary cards. In addition, investigators soli-
cited information on specific local AEs (swelling/
induration, redness and pain at injection site) and gen-
eral AEs (fever, headache, fatigue, muscle aches, sweat-
ing, joint pain and shivering) occurring within 7 days of
each vaccination. Symptom intensity was assessed on a
3-point scale where grade 3 represents the most intense.
For both unsolicited AEs and solicited general AEs, the
investigators determined the likely relationship of vacci-
nation to symptoms. Intensity and relationship to vacci-
nation of unsolicited local and general AEs were
recorded during a 21-day follow-up period from each
vaccine administration, as well as overall (Day 0 through
to Day 84). All solicited local (injection site) reactions
were considered causally related to vaccination. The
occurrence of SAEs was recorded during the entire
study (up to Day 182).
Haematological and biochemical parameter testing was
performed by SRL Medisearch Inc, Japan. The number
and percentage of subjects with normal or abnormal
haematological and biochemical values, and with normal
or abnormal urine values at Day 0, 7 and 42, were cal-
culated. An assessment of these haematological, bio-
chemical and urine parameters was performed at Day 7
and 21 - all parameters were reviewed at Day 7 by the
investigators before administering the second vaccine
dose at Day 21. Blood parameters assessed were com-
plete blood count, blood urea nitrogen (BUN), creati-
nine, alanine amino transferase (ALT) and aspartate
aminotransferase (AST). Urine parameters measured
were protein, glucose, blood and urobilinogen.
Statistical analysis
The statistical methods for all immunogenicity analyses
were performed using the per protocol group. The pri-
mary objective of this study was to evaluate the humoral
immune response induced by two doses of the H5N1
influenza candidate vaccine in terms of H5N1 HI anti-
body titres against the vaccine strain. The immunogeni-
city assessments were based on the surrogate HI
endpoints as required by regulatory authorities (CBER
and CHMP). In order to meet or exceed these immuno-
genicity guidance criteria, a target sample size of 100
subjects was required in order to ensure 90 evaluable
subjects. Taking into account a 10% drop-out rate and
considering a true seroconversion rate (SCR for HI anti-
bodies was defined as the percentage of subjects with
either a pre-vaccination titre <1:10 and a post-vaccina-
tion titre ≥1:40 or a pre-vaccination titre ≥1:10 and at
least a 4-fold increase in post-vaccination titre) of 83.7%
and a true seroprotection rate (SPR; defined as the per-
centage of subjects with a serum H5N1 HI antibody
titre ≥1:40) of 84.3%, the proposed sample size allowed
for an overall probability of above 85% of meeting the
lower limits of 95% confidence intervals (CIs) for SCRs
and SPRs of 40% and 70%, respectively. Ninety five per-
cent CIs were calculated for geometric mean titres
(GMTs) by exponential transformation of the 95% CI
for the mean of log-transformed titres, assuming normal
distribution of log-transformed titres.
The immunogenicity analysis was performed for each
age stratum and overall. The humoral immune response
endpoints in terms of H5N1 HI antibodies were mea-
sured using the GMTs of H5N1 HI antibody titres at
Day 0, 21, 42 and 182, SCR at Day 21, 42 and Day 182
and seroconversion factors (SCF; defined as the fold
increase in serum H5N1 HI antibody GMTs post-vacci-
nation compared with Day 0) at Day 21, 42 and Day
182. The CHMP cut off for SCF is defined as a ratio of
>2.5. SPRs were also calculated at Day 0, 21, 42 and
182. Seropositivity was defined as an HI titre >1:10.
For neutralizing antibodies, the endpoints (with 95%
CIs) were seropositivity, GMTs and SCRs (SCR for MN
antibodies was defined as the percentage of subjects
with at least four-fold increase in post-vaccination neu-
tralising antibody titres). The GMTs of neutralising anti-
body titres were calculated at Day 0, 42 and 182, and
the SCRs in terms of neutralising antibody titres were
calculated at Day 42 and 182.
The safety analysis was performed on all subjects
receiving at least one vaccination (the total vaccinated
cohort [TVC]). The percentage of subjects with at least
one local AE (solicited and unsolicited), at least one
general AE (solicited and unsolicited) and any AE dur-
ing the solicited follow-up period was tabulated, with
exact 95% CI after each vaccination and overall per sub-
ject considering both post-immunisation periods.
Solicited symptoms and any pain relief and/or antipyre-
tics taken by the subject to correct the symptoms of local
and/or general solicited symptoms were recorded during
the 7-day follow-up period after each H5N1 vaccination.
Results
A total of 100 subjects (n = 50 for 20-40 years of age;
n = 50 for 41-64 years of age) were enrolled in Septem-
ber 2008, all of whom received two doses of study vac-
cine by October 2008. The per protocol cohort was,
therefore, identical to the TVC. The mean age of the
vaccinated subjects (total cohort) was 40.3 years, 31.1
years for the 20-40 years’ stratum and 49.6 years for the
41-64 years’ stratum. The overall male-female distribu-
tion was 43% versus 57%. The demographic characteris-
tics of the subjects involved are shown in Table 1.
Immunogenicity and cross-clade antibody titres
Only five out of 100 subjects were seropositive against
the vaccine-homologous strain (A/Indonesia/5/2005;
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Page 4 of 10Clade 2.1) at Day 0 (before vaccination), of whom none
had a seroprotective HI titre of 1:40 or more. Pre-vacci-
nation HI GMTs against the other two vaccine-heterolo-
gous strains (A/Vietnam/1194/2004; Clade 1 and A/
turkey/Turkey/1/2005; Clade 2.2) were also very low
and were almost the same as for the vaccine-homolo-
gous strain.
Immune responses against the vaccine-homologous
strain (A/Indonesia/5/2005; Clade 2.1) at Day 42 fulfilled
and exceeded all CHMP and CBER criteria for HI anti-
body response (Table 2). Overall, the homologous HI
SCR and SPR were found to be 91% and were compar-
able for the predefined age strata (90% for 20-40 years,
92% for 41-64 years). A high cross-reactive (heterolo-
gous HI) humoral immune response was observed
against the A/turkey/Turkey/1/2005 strain (H5N1 Clade
2.2) and to a lower extent against the A/Vietnam/1194/
2004 strain (H5N1 Clade 1) after the second vaccine
administration. The HI antibody response against each
of the A/turkey/Turkey/1/2005 and A/Vietnam/1194/
2004 strains after two doses was similar across the pre-
defined age strata.
Persistence of the immune response was observed on
Day 182 (i.e., 6 months after the first dose); a substantial
proportion of subjects (in both age strata) were still ser-
opositive for H5N1 HI antibodies against the A/Indone-
sia/5/2005 strain (Clade 2.1) and the A/turkey/Turkey/
1/2005 strain (Clade 2.2) and, to a lower extent, against
the A/Vietnam/1194/2004 strain (Clade 1). The GMTs
for H5N1 HI antibodies decreased against all three
H5N1 strains compared with Day 42. On Day 182, all
three CHMP criteria were still met for H5N1 HI anti-
body responses against the A/Indonesia/5/2005 strain
(except the SPR threshold for subjects aged 20-40
years). Two of the three CHMP criteria (SCR and SCF)
f o rH 5 N 1a n t i b o d yr e s p o n s ea g a i n s tt h eA / t u r k e y / T u r -
key/1/2005 strain were still met in the 41-64 years age
stratum.
T r e n d sf o rh i g h e rH Ia n t i b o d yr e s p o n s e sw e r e
observed against both vaccine homologous and heterolo-
gous strains 21 days after the second vaccine dose, in
subjects who were seropositive before vaccination. This
must be interpreted with caution given the low number
of seropositive subjects before vaccination (N = 4 to 6).
Neutralising antibody response
Neutralising antibody response to the vaccine homolo-
gous and heterologous strains at different time points
have been presented in Table 3. A marked post-vaccina-
tion response in terms of neutralising antibody titres
(GMTs) was observed against both Clade 1 and Clade 2
viruses. The observed data suggested that pre-vaccina-
tion seropositivity rates against the A/Indonesia/5/2005
strain were low (11.1%) and were higher against the vac-
cine heterologous strain A/Vietnam/1194/2004 (50%).
Following vaccination, the seropositivity rates for neu-
tralising antibody titres against the A/Indonesia/5/2005
strain and the A/Vietnam/1194/2004 strain were
increased at Day 42, reaching 100% and 95%,
respectively.
The SCR for neutralising antibodies increased after the
second vaccination and reached 97% and 47% at Day 42
against the A/Indonesia/5/2005 strain and the A/Viet-
nam/1194/2004 strain, respectively. Six months after the
first vaccination, high seropositivity rates were observed
in terms of H5N1 neutralising antibodies against both
A/Indonesia/5/2005 (100%) and A/Vietnam/1194/2004
(92.9%). The SCR against the A/Indonesia/5/2005 and
the A/Vietnam/1194/2004 strains at 6 months were
93.9% and 58.6%, respectively.
Safety
Compliance in returning safety diary cards was excellent
(100%) for both general and local symptoms. There
were no SAEs and no withdrawals due to AEs.
Solicited local and general AEs are shown in Figures
2 and 3, respectively, and the proportion of subjects
reporting fever is shown in Figure 3. Pain at the injec-
tion site (of any grade) was the most frequently
reported local symptom in the overall cohort after
dose 1 (98%) and dose 2 (93%), and there was no
observable difference between age strata. The next
Table 1 Demographic data of trial subjects
20-40 Y 41-64 Y Total
N = 50 N = 50 N = 100
Characteristics Parameters or
Categories
Value
or n
% Value
or n
% Value
or n
%
Age (years) Mean 31.1 - 49.6 - 40.3 -
SD 5.69 - 6.04 - 10.89 -
Median 31 - 49 - 40.5 -
Minimum 20 - 41 - 20 -
Maximum 40 - 63 - 63 -
Gender Female 25 50 32 64 57 57
Male 25 50 18 36 43 43
Race Asian-Japanese
heritage
50 100 50 100 100 100
Height (cm) Mean 165.9 - 162.5 - 164.2 -
SD 8.41 - 7.46 - 8.1 -
Median 164 - 161.5 - 163 -
Weight (kg) Mean 60.7 - 60.6 - 60.6 -
SD 12.13 - 11.28 - 11.65 -
Median 61 - 57.6 - 59 -
20-40 Y = subjects aged 20-40 years; 41-64 Y = subjects aged 41-64 years;
N = total number of subjects;
n/% = number/percentage of subjects in a given category; value = value of
the considered parameter;
SD = standard deviation
Nagai et al. BMC Infectious Diseases 2010, 10:338
http://www.biomedcentral.com/1471-2334/10/338
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induration, followed by redness. Grade 3 pain was
reported in one subject in the 20-40 years’ stratum.
General solicited symptoms included fatigue (most
common, reported by 71% of subjects overall) followed
by muscle aches (70% overall) and headache (51%
overall).
Overall, 69% of the subjects reported at least one
unsolicited AE, with nasopharyngitis (18%) and injection
site pruritus (18%) as the most frequently reported
unsolicited AEs in the 20-40 year and 41-64 year
cohorts, respectively. There were no major or clinically
relevant differences between age strata for any AE and
no specific clinical pattern of unsolicited AEs could be
Table 2 Haemagglutination inhibition (HI) antibody immune responses to homologous and heterologous H5N1
influenza strains following one or two doses of the AS03A-adjuvanted A/Indonesia/5/2005 (H5N1) influenza vaccine
were assessed in terms of seropositivity rates, GMTs, SCRs, SCFs and SPRs
Seropositivity rates GMT SCR
(Negative pre-
vaccination HI titre
and P/V HI titre ≥1:40,
or proportion with ≥4-
fold increase from pre-
to post vaccination)
SCF
(Mean GMT
increase in titre
>2.5 [adults]; >2.0
[aged over 60 y])
SPR
(% subjects with P/V
HI titre ≥1:40)
Antibody Group D N n % (95% CI) Value (95% CI) N n % (95% CI) N Value (95% CI) N n % (95% CI)
A/Indonesia 20-40 Y 0 50 0 0.0 (0.0-7.1) 5.0 (5.0-5.0) - - - - - 50 0 0.0 (0.0-7.1)
21 50 24 48.0 (33.7-62.6) 15.8 (11.0-22.8) 50 19 38.0 (24.7-52.8) 50 3.2 (2.2-4.6) 50 19 38.0 (24.7-52.8)
42 50 45 90.0 (78.2-96.7) 156.8 (105.8-232.3) 50 45 90.0 (78.2-96.7) 50 31.4 (21.2-46.5) 50 45 90.0 (78.2-96.7)
182 49 30 61.2 (46.2-74.8) 25.6 (17.3-38.1) 49 29 59.2 (44.2-73.0) 49 5.1 (3.5-7.6) 49 29 59.2 (44.2-73.0)
41-64 Y 0 50 5 10.0 (3.3-21.8) 5.4 (5.0-5.8) - - - - - 50 0 0.0 (0.0-7.1)
21 50 27 54.0 (39.3-68.2) 15.4 (10.7-22.0) 50 16 32.0 (19.5-46.7) 50 2.8 (2.0-4.0) 50 16 32.0 (19.5-46.7)
42 50 48 96.0 (86.3-99.5) 142.1 (104.0-194.3) 50 46 92.0 (80.8-97.8) 50 26.2 (19.2-35.8) 50 46 92.0 (80.8-97.8)
182 50 40 80.0 (66.3-90.0) 37.4 (27.5-50.8) 50 38 76.0 (61.8-86.9) 50 6.9 (5.1-9.2) 50 38 76.0 (61.8-86.9)
A/turkey/Turkey 20-40 Y 0 50 2 4.0 (0.5-13.7) 5.7 (4.8-6.8) - - - - - 50 2 4.0 (0.5-13.7)
21 50 13 26.0 (14.6-40.3) 8.0 (6.1-10.4) 50 3 6.0 (1.3-16.5) 50 1.4 (1.1-1.8) 50 5 10.0 (3.3-21.8)
42 50 30 60.0 (45.2-73.6) 24.8 (16.6-37.1) 50 27 54.0 (39.3-68.2) 50 4.4 (3.0-6.5) 50 29 58.0 (43.2-71.8)
182 49 30 61.2 (46.2-74.8) 19.2 (13.4-27.3) 49 18 36.7 (23.4-51.7) 49 3.4 (2.4-4.7) 49 20 40.8 (27.0-55.8)
41-64 Y 0 50 2 4.0 (0.5-13.7) 5.2 (4.9-5.5) - - - - - 50 0 0.0 (0.0-7.1)
21 50 18 36.0 (22.9-50.8) 9.6 (7.3-12.5) 50 7 14.0 (5.8-26.7) 50 1.8 (1.4-2.4) 50 8 16.0 (7.2-29.1)
42 50 31 62.0 (47.2-75.3) 24.0 (16.1-35.6) 50 27 54.0 (39.3-68.2) 50 4.6 (3.1-6.8) 50 27 54.0 (39.3-68.2)
182 50 38 76.0 (61.8-86.9) 30.7 (22.2-42.5) 50 30 60.0 (45.2-73.6) 50 5.9 (4.2-8.2) 50 30 60.0 (45.2-73.6)
A/Vietnam 20-40 Y 0 50 1 2.0 (0.1-10.6) 5.2 (4.8-5.7) - - - - - 50 1 2.0 (0.1-10.6)
21 50 5 10.0 (3.3-21.8) 5.7 (5.0-6.5) 50 0 0 (0-7.1) 50 1.1 (1.0-1.2) 50 1 2.0 (0.1-10.6)
42 50 26 52.0 (37.4-66.3) 12.7 (9.5-17.1) 50 14 28.0 (16.2-42.5) 50 2.4 (1.8-3.2) 50 15 30.0 (17.9-44.6)
182 49 17 34.7 (21.7-49.6) 8.6 (6.8-10.8) 49 2 4.1 (0.5-14.0) 49 1.6 (1.3-2.1) 49 3 6.1 (1.3-16.9)
41-64 Y 0 50 5 10.0 (3.3-21.8) 5.9 (5.0-6.8) - - - - - 50 2 4.0 (0.5-13.7)
21 50 13 26.0 (14.6-40.3) 7.0 (5.8-8.5) 50 1 2.0 (0.1-10.6) 50 1.2 (1.1-1.4) 50 4 8.0 (2.2-19.2)
42 50 24 48.0 (33.7-62.6) 13.3 (9.7-18.2) 50 12 24.0 (13.1-38.2) 50 2.3 (1.7-3.0) 50 15 30.0 (17.9-44.6)
182 50 23 46.0 (31.8-60.7) 10.7 (8.2-13.9) 50 10 20.0 (10.0-33.7) 50 1.8 (1.4-2.4) 50 12 24.0 (13.1-38.2)
Subjects received one dose of vaccine on Day 0 and one dose on Day 21 (ATP cohort for immunogenicity and persistence).
20-40 Y = subjects aged 20-40 years; 41-64 Y = subjects aged 41-64 years; GMT = geometric mean antibody titre; N = number of subjects with available results;
n/% = number/percentage of subjects; P/V = post-vaccination; 95% CI = 95% confidence interval; D = Day, 0 = pre-vaccination, 21 = 21 days post vaccination
one, 42 = 42 days post vaccination one (i.e. 21 days post vaccination two), 182 = 182 post vaccination one.
Committee for Medicinal Products for Human Use (CHMP) criteria for adults 18-60 years: SCR >40%, SPR >70% and a SCF of >2.5
US Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) criteria for adults <65 years of age: Lower bound of the two-sided
95% CI for the percentage of subjects achieving seroconversion for HI antibody should meet or exceed 40% and the lower bound of the two-sided 95% CI for
the percentage of subjects achieving a seroprotective level of HI antibody titre ≥1:40 should meet or exceed 70%.
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Page 6 of 10identified in either group. Grade 3 unsolicited AEs and
grade 3 unsolicited AEs considered related to any vacci-
nation were infrequent and similar in both age strata
(20-40 years, three subjects with at least one symptom
and one of these symptoms considered by an investiga-
tor to be related to vaccination; 41-64 years, three
subjects reporting at least one symptom, no related
symptoms). No pattern was observed regarding bio-
chemical abnormalities.
Discussion
The results of this study demonstrate that the AS03A-
adjuvanted A/Indonesia/5/2005 (H5N1) vaccine was
well tolerated and induced strong humoral immune
responses in healthy Japanese adults.
The primary endpoints for this study were reached at
21 days after the second vaccination, with immune
responses fulfilling all CHMP and CBER criteria for
the vaccine-homologous HI antibody response (A/
Table 3 Neutralising antibody immune responses to homologous and heterologous H5N1 influenza strains following
one or two doses of the AS03A-adjuvanted A/Indonesia/5/2005 (H5N1) influenza vaccine in terms of seropositivity
rates and seroconversion rates
Antibody Time point N Seropositivity % (95% CI) N Seroconversion % (95% CI)
A/Indonesia PRE 99 11.1 (5.7-19.0) ––
Day 42 100 100 (96.4-100) 99 97.0 (91.4-99.4)
Day 182 99 100 (96.3-100) 98 93.9 (87.1-97.7)
A/Vietnam PRE 100 50.0 (39.8-60.2) ––
Day 42 100 95.0 (88.7-98.4) 100 47.0 (36.9-57.2)
Day 182 99 92.9 (86.0-97.1) 99 58.6 (48.2-68.4)
Subjects received one dose of vaccine on Day 0 and one dose on Day 21 (ATP cohort for immunogenicity and persistence).
Seroconversion rate for MN antibodies: Percentage of subjects with at least four-fold increase post-vaccination neutralising antibody titres.
Figure 2 Solicited local symptoms of any grade and grade 3 severities, following two doses of the AS03A-adjuvanted A/Indonesia/5/
2005 (H5N1) vaccine, given 21 days apart.
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Page 7 of 10Indonesia/5/2005, Clade 2.1). Overall, homologous HI
SCR and SPR were 91% and no differences between the
predefined age strata were observed (90% for 20-40
years, 92% for 41-64 years).
These responses were achieved with low doses of anti-
gen (3.75 μgH A ) .T h e‘antigen-sparing’ effect of the
adjuvant AS03 was not demonstrated in this study, as
no comparison was made with an unadjuvanted formu-
lation containing 3.75 μg HA; however, the current
s t u d yi si nl i n ew i t hp r e v i o u s influenza vaccine studies
with this adjuvant formulation which have shown that
the AS03-adjuvanted H5N1 vaccines induce a substan-
tially higher immune response than non-adjuvanted for-
mulations [9], with antigen-sparing properties [10-12].
Therefore, the AS03 adjuvant plays a key role in provid-
ing high levels of immunity at relatively low antigen
doses, which is one of the requirements for a viable pan-
demic vaccine in the context of mass distribution.
The H5N1 A/Indonesia/5/2005 vaccine described here
was tested in a two-dose regimen with responses to the
vaccine strain that met CHMP and CBER criteria only
at 21 days after the second injection. This is in contrast
to the GSK Biologicals’ A/California/7/2009 H1N1 pan-
demic vaccine adjuvanted with AS03A (Pandemrix™)
which was licensed for use in the 2009/2010 H1N1 pan-
demic [23]. While posology guidelines published by the
European Medicines Agency indicate that a second dose
of the vaccine may be desirable to achieve maximum
seroprotection, data suggest that a single dose of the
H1N1 vaccine may be sufficient to achieve this in
healthy adults aged 18-60 years [23]. The reason for this
difference may be that naturally acquired partial
immunity against A/California/7/2009 (H1N1) is more
common, due to prior exposure to circulating H1N1
strains with epitopes similar to those found in A/Cali-
fornia/7/2009 (H1N1).
In the current study, SCR and SPR of more than 54%
for H5N1 HI antibodies against the Clade 2.2 A/turkey/
Turkey/1/2005 were observed after two doses in each
age stratum, indicating that the vaccine was markedly
cross-immunogenic. This was also observed, albeit to a
lesser extent, against the A/Vietnam/1194/2004 (Clade
1) strain, where SCR and SPR of more than 24% were
observed. This finding is similar to those of previous
studies with the AS03-adjuvanted H5N1 vaccine formu-
lated with the A/Vietnam/1194/2004 (Clade 1) strain
where significant levels of cross-clade immunogenicity
were observed against antigenically distinct strains of
H5N1, including the strains from the other Clades
[9,10,12,13]. In a study in Asian adults, following two
doses of the AS03-adjuvanted H5N1 vaccine, seropro-
tection rates in terms of HI antibodies against the
vaccine homologous (A/Vietnam/1194/2004) and het-
erologous (A/Indonesia/5/2005) strains were 94.3% and
50.2%, respectively. For neutralising antibodies against
the A/Vietnam/1194/2004 and A/Indonesia/5/2005
(Clade 2.1) strains, seroconversion rates were 96% and
91.4%, respectively [9]. In another study in Europe, two
doses of the H5N1 vaccine elicited strong immune
responses against vaccine heterologous A/turkey/Tur-
key/1/2005 (Clade 2.2) and A/Anhui/1/2005 (Clade 2.3)
strains (neutralising seroconversion rates: 75- 85%). The
study also reported persistence of neutralising serocon-
version rates in 60-70% of subjects, up to six months
Figure 3 Solicited general symptoms of any grade and grade 3 severities, following two doses of the AS03A-adjuvanted A/Indonesia/
5/2005 (H5N1) vaccine, given 21 days apart.
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Page 8 of 10after vaccination [12]. The trend for higher immune
responses observed against A/turkey/Turkey/1/2005
may be explained by its lower antigenic distance with
the vaccine strain (both are Clade 2 strains) a trend also
observed previously [12], in comparison with the A/
Vietnam/1194/2004 strain which belongs to Clade 1.
H5N1 influenza vaccine efficacy cannot be evaluated in
humans for obvious reasons; however, recent studies in
a robust ferret model have shown high levels of protec-
tion against heterologous challenge following vaccina-
tion with a split-virion A/H5N1/Vietnam/1194/04
vaccine formulated with AS03 [15].
Although a substantial proportion of subjects were
still seropositive 6 months after vaccination, a reduction
of the vaccine response was observed in both age strata
for all three strains. However, the data of Schwarz et al.
[13] showed effective boosting of immune responses 6
months after primary vaccination. This indicates that
the waning response observed at 6 months in this study
could be restored by a single booster vaccination with a
homologous or heterologous strain.
Moderate levels of baseline seropositivity have already
been observed in other populations, particularly for the
A/Vietnam strain. In a previous study in a large Asian
population, ≤7.2% of subjects was seropositive for the
A/Vietnam strain prior to vaccination [9]. The fact that
the seropositivity was observed in individuals aged >55
years may concur with repeated exposure to conserved
epitopes of seasonal influenza antigens (either through
vaccination or natural infection), possibly at the origin
of a moderate cross-reactogenic response; this is sup-
ported by several reports that showed cross-reactivity
between human and avian strains [24-27].
The reactogenicity and safety profiles reported in
healthy Japanese adults were similar to those seen in
other studies conducted in adults using split-virion,
AS03-adjuvanted formulations [9-13], with pain (of any
grade) at the injection site being the most common
local solicited AE. These findings are in line with pre-
vious studies. The safety profile was otherwise unre-
markable, with the most common general solicited
symptom being fatigue.
T h eh i g h l yp a t h o g e n i ca v i a nH 5 N 1h a sc o n t i n u e dt o
evolve and diversify over the last decade. The H5 Hae-
magglutinin (HA) gene, which is the target of choice for
the adaptive immune response has been conspicuous in
its presence in all isolates since 1996. Data available
with the WHO indicate that as of March 2009, at least
10 distinct clades have arisen due to genetic re-assort-
ment [28]. A recent modeling study has reported that
point mutations in the H5 gene may have led to the
evolution of 20 genetically and potentially antigenically
distinct strains [29]. The WHO recommends that
individual national authorities be consulted and
epidemiological and geographical distribution of circu-
lating H5N1 strains be evaluated to decide on the speci-
fic H5N1 viruses to be used in H5N1 prepandemic
vaccines for respective countries [30]. The vaccine strain
(A/Indonesia/5/2005) in this study though first isolated
in 2005 was a dominant strain at the time of conduct of
this study and was recommended by the WHO for that
year; as of February 2010, the WHO has not proposed
any new H5N1 strain for vaccine development purposes
[30].
Conclusions
The H5N1 candidate vaccine adjuvanted with AS03A eli-
cited a strong and persistent immune response both
against the vaccine strain and two strains heterologous
to the vaccine in Japanese adults, together with clinically
acceptable reactogenicity and safety profiles.
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